Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
Sherene Loi(The University of Melbourne), Roberto Salgado(Peter MacCallum Cancer Centre), Giuseppe Curigliano(University of Milan), Roberto Iván Romero Díaz(Instituto Tecnológico de Oaxaca), Suzette Delaloge(Institut Gustave Roussy), Carlos Ignacio Rojas García(Clinica Santa Maria), Marleen Kok(Dutch Cancer Society), Cristina Saura(Hebron University), Nadia Harbeck(Ludwig-Maximilians-Universität München), Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Denise A. Yardley(Sarah Cannon), Alberto Suárez Zaizar(MSD (Mexico)), Facundo Rufino Caminos(Servicio Diabetología Hospital Córdoba), Andrei Ungureanu(Physiotherapy New Zealand), Joaquin G. Reinoso-Toledo(Universidad Interamericana del Norte), Valentina Guarneri(University of Padua), Daniel Egle(Innsbruck Medical University), Felipe Ades(Bristol-Myers Squibb (Sweden)), Misena Pacius(Bristol-Myers Squibb (Sweden)), Aparna Chhibber(Bristol-Myers Squibb (Sweden)), Rajalakshmi Chandra(Bristol-Myers Squibb (Sweden)), Raheel Nathani(Bristol-Myers Squibb (Sweden)), Thomas Spires(Bristol-Myers Squibb (Sweden)), Jenny Wu(Bristol-Myers Squibb (Sweden)), Lajos Pusztai(Smilow Cancer Hospital), Heather L. McArthur(The University of Texas Southwestern Medical Center)
Cited by 0Open Access
Abstract
What is this summary about?
Related Papers
No related papers found
Powered by citation graph analysis